YANG, Lan; MA, Aixia. Cost-utilities Analysis of Polatuzumab Vedotin Combined with Bendamustine and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation. Frontiers in Business, Economics and Management, [S. l.], v. 8, n. 3, p. 178–184, 2023. DOI: 10.54097/fbem.v8i3.7835. Disponível em: https://drpress.org/ojs/index.php/fbem/article/view/7835. Acesso em: 20 may. 2026.